Business Context and Reporting Period
AptarGroup, Inc. (NYSE: ATR) is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The company serves pharmaceutical, beauty, food, beverage, personal care, and home care markets. This Form 10-K covers the fiscal year ended December 31, 2024. Aptar operates through three reporting segments: Aptar Pharma, Aptar Beauty, and Aptar Closures. As of December 31, 2024, the company employed approximately 13,500 people across 20 countries.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Sales | $3.58 billion | $3.49 billion | +3.0% |
| Net Income | $374.2 million | $284.2 million | +31.7% |
| Diluted EPS | $5.53 | $4.25 | +30.1% |
| Operating Income | $496.5 million | $404.0 million | +22.9% |
| Operating Margin | 13.8% | 11.6% | +220 bps |
| Adjusted EBITDA | $774.9 million | $707.7 million | +9.5% |
| Adjusted EBITDA Margin | 21.6% | 20.3% | +130 bps |
| Free Cash Flow | $366.9 million | $262.9 million | +39.6% |
| Total Debt | $1.03 billion | $1.14 billion | -9.9% |
| Cash & Equivalents | $223.8 million | $223.6 million | +0.1% |
| Net Debt to Net Capital | 24.4% | 28.3% | -390 bps |
Material Changes vs. Prior Period
- Revenue Growth: Core sales grew 3% year-over-year, driven by favorable product mix and volume growth, particularly in prescription drug delivery and active material science solutions. Currency translation had a negligible impact.
- Profitability Expansion: Operating income increased 23% to $496.5 million. This was driven by strong sales growth in the Pharma segment, a lower cost of sales percentage (62.2% vs. 63.8%), and significantly reduced restructuring costs ($13.0 million in 2024 vs. $45.0 million in 2023).
- Segment Performance:
- Aptar Pharma: Net sales increased 8% to $1.64 billion; Adjusted EBITDA margin improved to 34.6%.
- Aptar Beauty: Net sales decreased 3% to $1.23 billion due to lower tooling sales and difficult European comparisons; Adjusted EBITDA margin improved slightly to 13.0%.
- Aptar Closures: Net sales increased 2% to $714.0 million; Adjusted EBITDA margin improved to 16.0%.
- Acquisitions: In October 2024, the company acquired a 40% equity interest in Goldrain (Ningbo Jinyu Technology Industry Co., Ltd.) for approximately $99 million. Smaller acquisitions of iD SCENT and Gulf Closures occurred in 2023.
- Capital Allocation: The company repurchased approximately 218,000 shares in Q4 2024 for $37.3 million. A new $500 million share repurchase authorization was approved in October 2024. Dividends paid totaled $114.1 million in 2024.
Guidance, Outlook, and Risks
- Q1 2025 Guidance: Management expects diluted earnings per share (excluding restructuring, fair value changes, and acquisition costs) to be in the range of $1.11 to $1.19. This guidance assumes an effective tax rate of 25% to 27% and is based on spot rates as of December 31, 2024.
- Currency Headwinds: Management anticipates a larger currency headwind in Q1 2025 due to the renewed strength of the U.S. dollar against many currencies.
- Capital Expenditures: Expected to range between $280 million and $300 million in 2025.
- Key Risks:
- Geopolitical & Trade: Potential impacts from new U.S. tariffs announced in January 2025 on imports from China, Canada, and Mexico, and related countermeasures.
- Supply Chain: Reliance on single-source suppliers for certain raw materials (e.g., resins for Pharma) and potential disruptions.
- Regulatory: Evolving environmental regulations regarding plastic waste, recycling, and PFAS bans in the EU and U.S.
- Cybersecurity: Increasing threats to data integrity and operational infrastructure.
Investor Verification Checklist
- Pharma Segment Drivers: Verify the sustainability of the 15% core sales growth in the prescription drug market and the impact of royalty revenues.
- Beauty Segment Recovery: Assess the outlook for the Beauty segment, which saw a 3% sales decline, specifically regarding European demand and tooling sales volatility.
- Goldrain Integration: Monitor the integration progress and financial contribution of the new 40% stake in Goldrain.
- Tariff Exposure: Evaluate the specific impact of new 2025 U.S. tariffs on raw material costs and supply chain logistics.
- Goodwill Impairment: Review the annual goodwill impairment testing, particularly for the Injectables reporting unit, which was identified as a critical audit matter.
- Debt Refinancing: Confirm the interest rate environment impact on the new Term Loan and amended revolving credit facility.